Diffusion-weighted MRI in Creutzfeldt-Jakob disease: A better diagnostic marker than CSF protein 14-3-3?

Journal of Neuroimaging

Volumn 13, Issue 2, 2003, Pages 147-151

  Mendez, Oscar E ^a   Shang, Jingzi ^a   Jungreis, Charles A ^a   Kaufer, Daniel I ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b 810 Liliane Kaufmann Building ^*  (United States)

Author keywords

Creutzfeldt Jakob disease; CSF; Diffusion MRI; Protein 14 3 3

Indexed keywords

BRAIN PROTEIN; PROTEIN 14 3 3;

AGED; ARTICLE; ATAXIA; BIOPSY; CASE REPORT; CLINICAL FEATURE; CREUTZFELDT JAKOB DISEASE; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; DISEASE MARKER; ELECTROENCEPHALOGRAPHY; FEMALE; GRAY MATTER; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN CEREBROSPINAL FLUID LEVEL; TREATMENT PLANNING;

14-3-3 PROTEINS; AGED; CREUTZFELDT-JAKOB SYNDROME; FATAL OUTCOME; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; TYROSINE 3-MONOOXYGENASE;

EID: 0037380248     PISSN: 10512284     EISSN: None     Source Type: Journal    
DOI: 10.1177/1051228403251085     Document Type: Article

References (23)

1. Pruisner SB. Shattuck lecture - neurodegenerative diseases and prions. N Engl J Med 2001;344:1516-1526.
2. Hsieh G, Kenney K, Gibbs CJ, Lee KH, Harrington MG. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996;335:924-930.
3. Zerr I, Pocchiari M, Collins S, et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000;55:811-815.
4. Poser S, Mollenhauer B, Krauß A, et al. How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain 1999;122:2345-2351.
5. Green AJE, Thompson EJ, Stewart GE, et al. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2001;70(6):744-748.
6. World Health Organization. Diagnosis and therapy of human transmissible spongiform encephalopathies. In: WHO Report of a WHO Consultation on Global Surveillance. Geneva, Switzerland: World Health Organization; 1998.
7. Knopman DS, Dekosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2001;65:1143-1153.
8. Burkhard PR, Sanchez J-C, Landis T, Hochstrasser DF. CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology 2001;56:1528-1533.
9. Irani DV, Ker DA. 14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis. Lancet 2000;355:901.
10. Saiz A, Graus F, Dalmau J, Pifarre A, Marin C, Tolosa E. Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann Neurol 1999;46:774-777.
11. Collie DA, Sellar RJ, Zeidler M, Colchester ACF, Knight R, Will RG. MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol. Clin Radiol 2001;56:726-739.
12. Schroter A, Zerr I, Henkel K, Tschampa HJ, Finkenstaedt M, Poser S. Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. Arch Neurol 2000;57:1751-1757.
13. Poon MA, Stuckey S, Storey E. MRI evidence of cerebellar and hippocampal involvement in Creutzfeldt-Jakob disease. Neuroradiol 2001;43:746-749.
14. Demaerel P, Heiner L, Robberecht W, Sciot R, Wilm G. Diffusion-weighted MRI in sporadic Creutzfeldt-Jakob disease. Neurology 1999;52:205-208.
15. Matoba M, Tonami H, Miyaji H, Yokota H, Yamamoto I. Creutzfeldt-Jakob disease: serial changes on diffusion-weighted MRI. J Comput Assist Tomogr 2001;25:274-277.
16. Mittal S, Farmer P, Kalina P, Kingsley PB, Halperin J. Correlation of diffusion-weighted magnetic resonance imaging with neuropathology in Creutzfeldt-Jakob disease. Arch Neurol 2002;59:128-134.
17. Samman I, Schulz-Schaeffer WJ, Wöhrle JC, Sommer A, Kretzschmar JD, Hennerici M. Clinical range and MRI in Creutzfeldt-Jakob disease with heterozygosity at codon 129 and prion protein type 2. J Neurol Neurosurg Psychiatry 1999;67:678-681.
18. Geschwind MD, Miller D, Martindale JL, et al. Challenging the clinical utility of the 14-3-3 protein in cerebrospinal fluid as a diagnostic marker for Creutzfeld-Jakob disease. Neurology 2002;58(Suppl 3):A250.
19. Bahn M, Parchi P. Abnormal diffusion-weighted magnetic resonance images in Creutzfeldt-Jakob disease. Arch Neurol 1999;56:577-583.
20. Yee AS, Simon JH, Anderson CA, Sze CI, Filley CM. Diffusion-weighted MRI of right-hemisphere dysfunction in Creutzfeldt-Jakob disease. Neurology 1999;52:1514-1515.
21. Kropp S, Finkenstaedt M, Zerr I, Schroter A, Poser S. Diffusionsgewichtetes MRT bei Creutzfeldt-Jakob patienten. Nervenarzt 2000;71:91-95.
22. Romi F, Simivoll AL, Mork S, Tysnes OB. Diffusion-weighted magnetic resonance tomography: a new instrument in the diagnosis Creutzfeldt-Jakob disease. Tidsskr Nor Laegeforen 2000;120:675-677.
23. Yang M-D, Braff SP, Nagle KJ, Pendlebury W, Penar PL, Shapiro RE. Emerging pattern of diffusion-weighted MR imaging in Creutzfeldt-Jakob disease: case report and review of the literature. Am J Neuroradiol 2002;23:550-556.